Beijing MTR was established on 16 January 2006 as a joint venture, with Beijing Infrastructure Investment holding 2% and Beijing Capital Group and MTR Corporation each holding 49%, according to the original entry. The profile describes public-private partnership investment, construction and operation of Beijing Lines 4, 14 and 16, management of Daxing Line, and planned leased operation of Line 17. It reported a portfolio of 196.8 kilometers, with approximately 125 kilometers and 78 stations then in operation, and full scores for the eastern and western sections of Line 14 and Line 16 in Beijing's 2020 operating assessments.
BIOSUN provides air treatment solutions for rail transit. Its Chinese project profile reports experience across more than 100 rail projects in China and overseas, with applications addressing airborne microorganisms, particles, chemical gases and emissions from interior materials in occupied transport environments.
Applications cover train interiors, platforms, station halls and public restrooms. BIOSUN applies PHOTOPLASMA technology to selected microbial, gaseous and particulate air treatment requirements. Performance should be assessed against the equipment specifications, relevant test reports and operating conditions.
